USA flag logo/image

An Official Website of the United States Government

Meta-Molding Arrays

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66411
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
DK062593
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
SYNTRIX BIOSYSTEMS, INC.
215 CLAY ST NW, STE B-5 AUBURN, WA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Meta-Molding Arrays
Agency: HHS
Contract: 1R43DK062593-01A1
Award Amount: $500,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Protein chips offer the potential to profile the levels and kinetics of proteins in tissues of the digestive and endocrine systems in a highly multiplexed format. Despite this potential, the majority of protein chips are based on arrayed bio-molecules obtained from biologic or enzymatic sources. Chips that rely on biology or enzymes suffer from several inherent shortcomings that include a restricted bio-molecule repertoire that is time-consuming and costly to manufacture, especially at high-density. We propose to overcome these limitations by developing a Meta-Molding array technology that consists of arrays of novel synthetic antibody mimetics. Mimetics will be identified using a novel and purely chemical discovery paradigm termed PNAdisplay. Consistent with previous studies in the field of dynamic combinatorial chemistry, we hypothesize that PNA-display will permit us to screen large heterodimer populations and identify at least moderate affinity mimetics in a facile system (i. e. < 10 (M). Arrays of such moderate-affinity mimetics employed with an orthogonal analytical method such as MALDI-TOF will provide an analytical capability exceeding that of antibody arrays alone, but without the disadvantages. This SBIR Phase I proposal is designed to prove the feasibility of using PNA-display to identify at least moderate affinity mimetics. Feasibility will set the stage to move into an aggressive Phase II program to develop a Meta-Molding array that monitors global intracellular signaling by detecting specific phosphopeptides. Inappropriate intracellular phosphorylation results in several diseases, including cancer, non-insulin dependent diabetes, and peripheral neuropathies. Syntrix will commercialize the Meta-Molding arrays that result from this research through third-party joint ventures.

Principal Investigator:

John A. Zebala

Business Contact:

John Zebala
4258679692
JZEBALA@EARTHLINK.NET
Small Business Information at Submission:

SYNTRIX BIOSYSTEMS, INC.
SYNTRIX BIOSYSTEMS, INC. BOX 166, 16625 REDMOND WAY NE, STE M REDMOND, WA 98052

EIN/Tax ID: 911981291
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No